Boston Scientific (NYSE: BSX) spent $2.9 billion on selling, general & administrative (SG&A) expense in 2016, and the figure increased to $3.6 billion in 2018, driven by the growth in sales, and launch of new products. As a percentage of revenue, SG&A declined from 39% in 2016 to 36% in 2018...
